BIODESIX, INC. Payments of Stock Issuance Costs
BIODESIX, INC. (BDSX) reported Payments of Stock Issuance Costs of $3.07 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-06.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2023-03-06
- BIODESIX, INC. payments of stock issuance costs for fiscal 2022 was $3.07M, a 362.20% increase from fiscal 2021.
- BIODESIX, INC. payments of stock issuance costs for fiscal 2021 was $664.00K, a 91.94% decline from fiscal 2020.
- BIODESIX, INC. payments of stock issuance costs for fiscal 2020 was $8.24M, a 274666.67% increase from fiscal 2019.
- BIODESIX, INC. payments of stock issuance costs for fiscal 2019 was $3.00K.
| Period end | Payments of Stock Issuance Costs 12 month |
|---|---|
| 2022-12-31 | $3.07M 10-K · filed 2023-03-06 |
| 2021-12-31 | $664.00K 10-K · filed 2023-03-06 |
| 2020-12-31 | $8.24M 10-K · filed 2022-03-14 |
| 2019-12-31 | $3.00K 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |